Cargando…

Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM

Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placeb...

Descripción completa

Detalles Bibliográficos
Autores principales: Fautrel, Bruno, Kirkham, Bruce, Pope, Janet E., Takeuchi, Tsutomu, Gaich, Carol, Quebe, Amanda, Zhu, Baojin, de la Torre, Inmaculada, De Leonardis, Francesco, Taylor, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780319/
https://www.ncbi.nlm.nih.gov/pubmed/31492040
http://dx.doi.org/10.3390/jcm8091394
_version_ 1783457104997122048
author Fautrel, Bruno
Kirkham, Bruce
Pope, Janet E.
Takeuchi, Tsutomu
Gaich, Carol
Quebe, Amanda
Zhu, Baojin
de la Torre, Inmaculada
De Leonardis, Francesco
Taylor, Peter C.
author_facet Fautrel, Bruno
Kirkham, Bruce
Pope, Janet E.
Takeuchi, Tsutomu
Gaich, Carol
Quebe, Amanda
Zhu, Baojin
de la Torre, Inmaculada
De Leonardis, Francesco
Taylor, Peter C.
author_sort Fautrel, Bruno
collection PubMed
description Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placebo in the 52-week RA-BEAM phase III study. Adults with active RA and inadequate response to methotrexate received baricitinib 4 mg once daily, adalimumab 40 mg every two weeks or placebo, with background methotrexate. Patients (N = 1010) were categorised as in remission, in remission or low disease activity, or not in remission or low disease activity at week 24. For patients in remission or low disease activity (n = 310), improvements in mean pain and physical function scores at week 24 were significantly greater with baricitinib than placebo (p < 0.001 and p < 0.01, respectively) and adalimumab (p < 0.05 for both). For both outcomes, differences between adalimumab and placebo were not significant. The proportions of patients in remission or low disease activity with minimal or no pain and with normalised physical function were numerically greater with baricitinib than placebo. Baricitinib 4 mg once daily provided enhanced improvement in pain and physical function in patients with well-controlled RA, suggesting it may produce effects beyond immunomodulation.
format Online
Article
Text
id pubmed-6780319
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67803192019-10-30 Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM Fautrel, Bruno Kirkham, Bruce Pope, Janet E. Takeuchi, Tsutomu Gaich, Carol Quebe, Amanda Zhu, Baojin de la Torre, Inmaculada De Leonardis, Francesco Taylor, Peter C. J Clin Med Article Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placebo in the 52-week RA-BEAM phase III study. Adults with active RA and inadequate response to methotrexate received baricitinib 4 mg once daily, adalimumab 40 mg every two weeks or placebo, with background methotrexate. Patients (N = 1010) were categorised as in remission, in remission or low disease activity, or not in remission or low disease activity at week 24. For patients in remission or low disease activity (n = 310), improvements in mean pain and physical function scores at week 24 were significantly greater with baricitinib than placebo (p < 0.001 and p < 0.01, respectively) and adalimumab (p < 0.05 for both). For both outcomes, differences between adalimumab and placebo were not significant. The proportions of patients in remission or low disease activity with minimal or no pain and with normalised physical function were numerically greater with baricitinib than placebo. Baricitinib 4 mg once daily provided enhanced improvement in pain and physical function in patients with well-controlled RA, suggesting it may produce effects beyond immunomodulation. MDPI 2019-09-05 /pmc/articles/PMC6780319/ /pubmed/31492040 http://dx.doi.org/10.3390/jcm8091394 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fautrel, Bruno
Kirkham, Bruce
Pope, Janet E.
Takeuchi, Tsutomu
Gaich, Carol
Quebe, Amanda
Zhu, Baojin
de la Torre, Inmaculada
De Leonardis, Francesco
Taylor, Peter C.
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
title Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
title_full Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
title_fullStr Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
title_full_unstemmed Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
title_short Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
title_sort effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from ra-beam
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780319/
https://www.ncbi.nlm.nih.gov/pubmed/31492040
http://dx.doi.org/10.3390/jcm8091394
work_keys_str_mv AT fautrelbruno effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam
AT kirkhambruce effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam
AT popejanete effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam
AT takeuchitsutomu effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam
AT gaichcarol effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam
AT quebeamanda effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam
AT zhubaojin effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam
AT delatorreinmaculada effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam
AT deleonardisfrancesco effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam
AT taylorpeterc effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam